FDA Brief

Warning letters Drugs

FDA warning letter to

Maggie Jeffries, M.D. / Avanti Anesthesiology, LLC

High riskIssued Mar 3, 2023Posted Mar 14, 2023Center for Drug Evaluation and Research | CDER

FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.

What happened

FDA inspected Dr. Jeffries’ clinical site in Houston from July 19 to August 5, 2021, as part of its Bioresearch Monitoring Program. The agency found that she conducted Protocol ANES001 with diazepam, tramadol, ondansetron, and MKO Melt without an IND in effect and did not meet the exemption criteria. FDA also found informed-consent failures: subjects were not given a copy of the consent form, and the form did not identify experimental procedures or describe reasonably foreseeable risks.

What FDA found

  1. The investigator began and ran a clinical trial of diazepam, tramadol, ondansetron, and MKO Melt without submitting and having an IND in effect.

    21 CFR 312.20(a), 312.20(b), 312.40(a)
  2. The trial did not qualify for the IND exemption because it gave tramadol and diazepam to cataract-surgery patients at a dose and in a combination that significantly increased risks.

    21 CFR 312.2(b)(1)(iii)
  3. The investigator did not give subjects a copy of the informed consent form.

    21 CFR 50.27(a)
  4. The informed consent form did not identify experimental procedures or describe reasonably foreseeable risks.

    21 CFR 50.25(a)(1), (2)

What FDA wants

Within 15 business days of receipt, notify CDER’s Office of Scientific Investigations in writing of actions taken to prevent similar violations. If the investigator believes she complied, include reasoning and supporting information.

Who should pay attention

  • clinical investigators and sponsors running drug trials
  • IRBs and research sites
  • anesthesia and cataract surgery practices conducting research

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk